0001127602-15-020743.txt : 20150616
0001127602-15-020743.hdr.sgml : 20150616
20150616153241
ACCESSION NUMBER: 0001127602-15-020743
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150513
FILED AS OF DATE: 20150616
DATE AS OF CHANGE: 20150616
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOCRYST PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000882796
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 621413174
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4505 EMPEROR BOULEVARD
STREET 2: SUITE 200
CITY: DURHAM
STATE: NC
ZIP: 27703
BUSINESS PHONE: 919-859-1302
MAIL ADDRESS:
STREET 1: 4505 EMPEROR BOULEVARD
STREET 2: SUITE 200
CITY: DURHAM
STATE: NC
ZIP: 27703
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Barnes Alane P
CENTRAL INDEX KEY: 0001584348
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-23186
FILM NUMBER: 15934268
MAIL ADDRESS:
STREET 1: 1929 BRASSFIELD ROAD
CITY: RALEIGH
STATE: NC
ZIP: 27614
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2015-05-13
0000882796
BIOCRYST PHARMACEUTICALS INC
BCRX
0001584348
Barnes Alane P
4505 EMPEROR BLVD.
SUITE 200
DURHAM
NC
27703
1
VP, General Counsel & Corp Sec
Emp. Stock Option (Right to Buy)
5.45
2015-05-13
4
A
0
17000
0
A
2015-05-13
2023-08-08
Common Stock
17000
17000
D
On May 13, 2015, BioCryst Pharmaceuticals, Inc. initiated a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX7353 in healthy volunteers. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in August 2013 has been met. Therefore, 25% of the performance-based stock options vested on May 13, 2015.
/s/ Alane P. Barnes
2015-06-16